Sidra Medicine Research Translates Rare Genetic Variant Linked to Increased Colorectal Cancer Risk in Qatar

Sidra Medicine Research Translates Rare Genetic Variant Linked to Increased Colorectal Cancer Risk in Qatar

Zebrafish Study provides new insights into hereditary cancer risk and the potential for earlier detection

Doha, Qatar – 18 November 2026: Sidra Medicine, a member of Qatar Foundation, has contributed to a research study identifying the cancer-promoting effects of a rare genetic variant found in Qatar, marking an important step toward improving genetic risk assessment and early screening for hereditary colorectal cancer.

The study, conducted in collaboration with Hamad Bin Khalifa University (HBKU) using genomic data from the Qatar Precision Health Institute (QPHI), investigated a rare variant in the MLH1 gene, which is associated with Lynch syndrome, the most common inherited form of colorectal cancer. Published in the International Journal of Cancer, the findings provide new evidence that could help healthcare professionals better identify individuals at increased risk and inform future decisions about genetic testing and cancer surveillance.

The research focused on the MLH1 p.His112Arg variant, initially identified through an analysis of whole-genome sequencing data from 14,392 QPHI participants in five individuals with insufficient evidence to determine whether it increased an individual’s risk of developing cancer.

To investigate its potential impact, researchers at Sidra Medicine used CRISPR-Cas9 gene-editing technology to introduce the variant into human colorectal cancer modified cells then transplanted into zebrafish, allowing researchers to observe tumor development in a living organism. The transparency of zebrafish larvae makes them particularly valuable for studying cancer progression, enabling scientists to monitor changes in tumor growth over a relatively short period.

Dr. Sahar Isa Da’as of Sidra Medicine said: “Genetic databases built mostly from other populations often cannot tell us what a variant found in our own community means. The zebrafish gives us a fast, living system to test these variants directly. In days rather than months, we can see whether a variant behaves like a cancer-promoting change.”

The findings have important implications for hereditary cancer prevention and early detection. Individuals carrying pathogenic variants in DNA mismatch repair genes can face a significantly increased lifetime risk of colorectal cancer. Identifying these variants can help inform decisions about earlier and more frequent colonoscopy surveillance, as well as genetic testing for relatives who may share the same inherited risk.

While further clinical evaluation is needed before the findings can inform individual patient management, the research strengthens the scientific evidence available to support more accurate genetic risk assessments. It also highlights the potential of zebrafish models as a faster and effective approach to investigating other rare genetic variants identified in regional populations.

Dr. Amal Elfatih, Senior Research Specialist at the Qatar Precision Health Institute (QPHI), said: “This work shows how population genomics and functional models can be linked. Populations in our region are underrepresented in global genetic databases, so variants seen in research cohorts here are often left classified as uncertain. Resolving them is a shared effort. Each variant we resolve adds to the evidence base, so that screening and genetic testing can one day be directed to the people at genuine risk, and cancers caught earlier.”

The research also underscores the importance of collaboration between healthcare institutions, academic researchers, and national precision health initiatives in addressing gaps in global genomic knowledge. By combining population-level genetic data with experimental models, the study demonstrates how locally relevant research can contribute to a better understanding of inherited cancer risks and support the development of more personalized approaches to healthcare.

The research was funded by HBKU’s College of Health and Life Sciences and Sidra Medicine’s Research Department. The animal studies were approved by Sidra Medicine’s Institutional Animal Care and Use Committee.

The study, titled “MLH1 p.His112Arg Variant Is Associated With Increased Cancer Susceptibility,” was co-first-authored by Amal Elfatih of QPHI and Issam Tout of Sidra Medicine, with Dr. Sahar Isa Da’as of Sidra Medicine and Dr. Borbala Mifsud of HBKU serving as co-senior authors. The study is available in the International Journal of Cancer: https://doi.org/10.1002/ijc.70790

Continuing on the theme of groundbreaking research, Sidra Medicine and Qatar Precision Health Institute are hosting the 12th edition of its Precision Medicine and the Future of Genomics (PMFG) Summit 2026 from 7 to 9 December.  PMFG Summit 2026, will bring together leading international experts, researchers, and healthcare professionals to discuss advances in genomics, multi-omics, and precision medicine, with a focus on translating scientific discoveries into clinical practice. The event will provide a platform for knowledge exchange, research collaboration, and discussions on the future of personalized and preventive healthcare. To register, please visit: www.sidra.org/events.